SCRS Launches Diversity Awareness Program
Ellicott City, MD - The Society for Clinical Research Sites (SCRS) has recently launched an innovative new program, “Site Awareness and Best Practices for Inclusion of Diverse Populations in Research.” The program is aimed at developing a better understanding of the knowledge, expertise, and best practices at clinical research sites to meet the needs of an increasingly diverse United States population.
The project has been advocated and is being sponsored by the following industry leaders: Merck has signed on as the Premier Supporting Sponsor of this program, and additional sponsors include Janssen and the Pharmaceutical Research and Manufacturers of America (PhRMA) as Contributors, and Acurian at the Patron level.
This diversity awareness program was created to support efforts by research sites to meet the goals of the FDA’s Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data. The FDA’s plan prioritizes improvements in the quality of demographic subgroup data collection, reporting and analysis, encourages greater participation of diverse patients, and supports the transparency of subgroup data.
“We know that clinical trials often fail to recruit minority patients in sufficient numbers for subgroup analysis,” said Christine Pierre, President of SCRS. “Our members include sites with innovative and successful minority patient recruitment programs, and SCRS is in a unique position to gather and share the best practices from those sites.”
To find out more about becoming a sponsor of this program, contact Diana Foster, Vice President of Strategy and Development of SCRS, at diana.foster@myscrs.org.
About SCRS
SCRS is a global trade organization founded in 2012 which represents more than 4,000 research sites in 45 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Our Voice. Our Community. Your Success. Join the community and collaborate with the global experts in site sustainability. Visit MySCRS.org.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
